Delhi-based Mankind Pharma said it plans to invest ₹150 crore in its Paonta Sahib plant as well enhance its presence in the US in the next 18 months to generate revenue of $150 million from the international market by 2030.
The pharma major, which is targeting domestic revenues of ₹5,000 crore by the end of 2016, against ₹3,400 crore last year, announced in a release that it has been ranked fourth in the Indian market by IMS Health, a US-based healthcare information company. The company said it had logged 18 per cent growth and monthly sales of ₹240 crore of its over 1,000 brands across categories, such as antibiotics and antifungals.
RC Juneja, Chairman and Founder, Mankind Pharma, in the statement said: “We are identifying overseas markets, have entered the cosmetics segment and are strengthening ourselves in the cardiovascular and anti-diabetic drug categories.”
Published on July 16, 2015
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.